European Union: Food, Drugs, Healthcare, Life Sciences

The EU Pharma Package introduces a novel approach to combat antimicrobial resistance through transferable exclusivity vouchers that reward innovation in priority antimicrobials while simultaneously implementing stricter antibiotic stewardship measures. This regulatory framework attempts to resolve the fundamental tension between incentivizing pharmaceutical companies to develop new antibiotics and ensuring these critical medicines are used prudently to prevent further resistance development.

Belgium's federal Chamber of Representatives has adopted a comprehensive bill introducing significant changes to pharmaceutical reimbursement procedures, including simplified approval tracks, new combination therapy rules, and an 80 million EUR annual industry contribution. The legislation also addresses drug unavailability issues and postpones certain 2024 reforms until 2028, fundamentally reshaping the financial and operational landscape for pharmaceutical companies operating in Belgium.

The European Union has spent the last decade reshaping the digital regulatory landscape through landmark legislation such as the General Data Protection Regulation (GDPR) and the AI Act. The European Health Data Space (EHDS) Regulation is the next significant step in that evolution. While often described as a healthcare initiative, the EHDS is at its core a data governance framework designed to unlock the value of electronic health data while safeguarding fundamental rights and promoting innovation.